MultiHance (gadobenate dimeglumine; Gd-BOPTA, Bracco SpA, Milano, Italy) is a novel gadolinium-based contrast agent which has recently been made commercially available in Europe for magnetic resonance imaging of the liver. It combines the properties of a conventional extracellular fluid contrast agent with those of a liver-specific agent and has been shown in numerous clinical trials to improve the impact of magnetic resonance imaging for both the detection and characterization of focal liver masses. The present article briefly summarizes the safety and efficacy results of Phase I, II and III clinical studies carried out in almost 800 patient and non-patient volunteers in both Europe and the USA.